Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-BCMA CAR-NK cells

A preparation of umbilical cord blood (CB)-derived natural killer cells (NKs) expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-BCMA CAR-NK cells recognize, bind to and induce selective cytotoxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-BCMA CAR-natural killer cells
anti-BCMA CAR-NKs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search